Organon was a pharmaceutical company whose headquarters were based in Netherlands.
In the year 2007, the company was acquired by Schering-Plough Corporation, a company that is based in New Jersey. Organon was an active producer of pharmaceutical ingredients and it was acquired together with its sister company Intervet, that manufactured veterinary pharmaceuticals. In 2009, Schering-Plough merged with Merck under the name Merck & Co. Organon deals with production in various fields such as contraception, reproductive medicine, HRT, psychiatry, and anesthesia. Organon products are sold to international markets, and it uses various online channels in marketing and selling its products. The company was founded in 1923 by Dr. Saal Van Zwanenberg in Netherlands. Initially, Organon concentrated in the production of insulin, and in 1930s it started manufacturing estrogens. In 1948, the company acquired the Newhouse research site that was based in United Kingdom. In its period, Organon manufactured a significant number of compounds that were never adopted for use in medical purposes. However, those products were used for a variety of research.
In 2014, Organon was charged with misrepresentation of drug prices by United States government. The company was also charged with providing financial incentives that were deemed improper to nursing homes. These incentives were to be used to acquire market shares discounts so as to encourage the use of Remeron. To be restituted under Federal Anti-Kickback Statute, Organon paid $622,350. The company had gained a big name in 1953 when if initiated the production of cortisone. Later in 1962, it bought the Neder Cocainefabriek. Currently, Organon is known as Koninklijke Zwanenberg-Organon (KZO) after being fused with fibre producer AKU in 1969. Later the company became AKZO Nobel. While AKZo’s headquarters remained in Anhem, they were later relocated to Amstrerdam. Its manufacturing facilities are currently in Germany, Ireland, Japan, USA, United Kingdom, and Netherlands.